Thermo Fisher Scientific's stock rose 3.01% and reached a 52-week high amid strong market performance, with the Nasdaq-100 up 1.49% and the S&P 500 up 1.31%.
The company reported a projected revenue of $42.88 billion for 2024, reflecting robust demand across its diversified product portfolio. Additionally, Stifel analyst Daniel Arias upgraded the stock rating to Buy and raised the price target to $700, citing optimism about the company's recovery in the biopharma sector and a strategic partnership with NVIDIA to enhance drug discovery through AI integration.
This positive outlook, combined with ongoing growth strategies and innovations, positions Thermo Fisher favorably in the life sciences market, suggesting continued investor confidence and potential for further stock appreciation.
Wall Street analysts forecast TMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMO is 658.89 USD with a low forecast of 580.00 USD and a high forecast of 750.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
Wall Street analysts forecast TMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMO is 658.89 USD with a low forecast of 580.00 USD and a high forecast of 750.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 626.620
Low
580.00
Averages
658.89
High
750.00
Current: 626.620
Low
580.00
Averages
658.89
High
750.00
Stifel
Daniel Arias
Buy
maintain
$583 -> $700
2026-01-09
Reason
Stifel
Daniel Arias
Price Target
$583 -> $700
AI Analysis
2026-01-09
maintain
Buy
Reason
Stifel analyst Daniel Arias raised the firm's price target on Thermo Fisher to $700 from $583 and keeps a Buy rating on the shares. Considering the outlook for 2026, the firm believes Thermo is set up to have a solid year that pushes organic growth back into the mid-single-digits and EPS growth into the high-single-digits, the analyst tells investors.
TD Cowen
Buy
maintain
$654 -> $696
2026-01-07
Reason
TD Cowen
Price Target
$654 -> $696
2026-01-07
maintain
Buy
Reason
TD Cowen raised the firm's price target on Thermo Fisher to $696 from $654 and keeps a Buy rating on the shares. The firm adjusted targets in the life science tools space as part of a Q4 outlook. While the bar is higher for the Q4 results following the recent share rallies, many companies "already soft guided" 2026, the analyst tells investors in a research note. TD believes this sets room for upside in 2026.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TMO
Unlock Now
Evercore ISI
Vijay Kumar
Outperform
maintain
$610 -> $650
2026-01-05
Reason
Evercore ISI
Vijay Kumar
Price Target
$610 -> $650
2026-01-05
maintain
Outperform
Reason
Evercore ISI analyst Vijay Kumar raised the firm's price target on Thermo Fisher to $650 from $610 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.
BofA
Buy
maintain
$650 -> $700
2025-12-15
Reason
BofA
Price Target
$650 -> $700
2025-12-15
maintain
Buy
Reason
BofA raised the firm's price target on Thermo Fisher to $700 from $650 and keeps a Buy rating on the shares. The firm is updating it price targets for Life Sciences & Diagnostic Tools stocks under its coverage, the analyst tells investors. Headwinds are expected to fade, and markets are expected to normalize in 2026, firm adds. The firm believes the biggest upside for the sector will be a return to spending by Biopharma, leading BofA to favor companies with higher exposure to research and development.
About TMO
Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. It also provides purification and filtration technologies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
